OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-04-01-accounts

MANTRRA: “MANchester Teaching and Research for RAre Disease

Annual Report

March 9[th] 2025

1. Introduction

MANTRAA was set up as a CIO in September 2019. The main objectives of the CIO are to advance and promote the science and medical practice of Rare Disease Genomic Medicine To this end MANTRAA aims to:

  1. Further education in Rare Genetic Diseases, supporting those who have an interest in this area to diagnose, understand, prevent, alleviate and cure congenital malformations and rare genetic disorders

  2. Support rare disease meetings, specifically the biannual Manchester Dysmorphology Conference. The first one was organized in 1984 by Professor Dian Donnai. Over the years, this biennial conference has brought experts within the field of genomic syndromology together from around the globe, to share knowledge and ideas which further our understanding of developmental disorders and congenital malformations. The conference aims to provide cutting edge content and a welcoming, relaxed setting to encourage discussions, forge collaborations and inspire new ways of improving the lives of patients.

  3. Support training through bursaries and scholarships

  4. Aid the collation and dissemination of reports, statements and research findings

2. Changes to Trustees 2024-2025

Jill Clayton-Smith ended her membership. Sofia Douzgou Houge (SDH) is resident in Bergen, Norway. All trustees agree to close the charity within the following financial year.

3. Activities February 2024- February 2025

c) Meeting support

The 2024 Manchester European Society of Human Genetics (ESHG) Syndromology and Dysmorphology Course: the course was held in Manchester, October 22[nd] - 24[th] , 2024. It was advertised on the ESHG website, the Manchester Rare Conditions Centre (MRCC) website and on relevant social media platforms. We reviewed 134 applications and 74 national, and international (Manchester to Hong Kong) attendees were offered participation. Speakers (18) from countries across the European continent were invited. Feedback from attendees was very positive with an average rating around overall organization of the course 4.79/5.

We have had some discussions with Dr Grace Vassallo and Dr Gareth Evans who hosted the Euro NF1 and NF2 conference in 2022. Neurofibromatosis 1 and 2 are multisystem disorders, with NF2 being very rare. Individuals with these disorders need specialist care and its important to train GPs and other doctors to both recognise signs of these disorders and to be able to help with specialist management. We have agreed to support educational initiatives in the future, particularly training expenses for doctors.

d) Education

We continue to contribute to other educational initiatives through our links with the European Reference Network for Congenital Anomalies, ERN ITHACA. SB and SD have continued to participate in teaching activities in Europe, the UK and overseas. ERN ITHACA sponsored fellowships for the ESHG and MRCC course too.

We continue to contribute to publications for rare conditions in the scientific medical literature.

4. 2025-2026 Plans

5. Accounts

These were verified over email.

We declare no further income this year.

We will have to pay an accountant for audit as per the Charity commission rules. That charge will be added to our account later.

Our expenditure was for support for NF team (see point 3c).

Date Item Receipt Expenditure
February 2024 Starting balance £39,194.05 of
which
£9,472.00
donation
from
Convenzis
Group (NF
conference
net income)
November 2023 Transfer to Dr G
Vassallo for NF1
MDT expenses
-£312,31
April 2024 Transfer to Dr G
Vassallo for NF1
MDT expenses
-£269,90
November 2024 Transfer to Dr G
Vassallo for NF1
MDT expenses
-£299,35
Totals £38,312.44 of
which
£8,590.44 NF
fund

BALANCE £38,312.44 as of February 2025

Report compiled March 2025 by Sofia Douzgou Houge and Siddharth Banka